Meeting
2013 ASCO Annual Meeting
High-dose interleukin-2 (HD IL-2) in the treatment of advanced melanoma: The University of Pittsburgh experience.
Authors
Diwakar Davar
University of Pittsburgh, Pittsburgh, PA
Diwakar Davar , Melissa Saul , Ahmad A. Tarhini , An Tran , Kerry Trent , Cindy Sander , John M. Kirkwood , Hussein Abdul-Hassan Tawbi
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Melanoma/Skin Cancers
Track
Melanoma/Skin Cancers
Sub Track
Melanoma/Skin Cancers
Citation
J Clin Oncol 31, 2013 (suppl; abstr 9075)
DOI
10.1200/jco.2013.31.15_suppl.9075
Abstract #
9075
Poster Bd #
48F
Abstract Disclosures
Similar Posters
Poster
2024 ASCO Annual Meeting
Dynamics of circulating cytokines and chemokines during and after tumor-infiltrating lymphocyte cell therapy with lifileucel in advanced melanoma patients.
First Author: Rongsu Qi
Poster
2022 ASCO Annual Meeting
Trial in progress: A phase 1-2, first-in-human, open label, dose escalation and expansion study of AU-007, a monoclonal antibody that binds to IL-2 and inhibits IL-2Rα binding, in patients with advanced solid tumors.
First Author: James Robert Vasselli
Poster
2022 ASCO Annual Meeting
First-in-human clinical trial of an oncolytic adenovirus armed with TNFa and IL-2 in patients with advanced melanoma receiving adoptive cell transfer of tumor-infiltrating lymphocytes.
First Author: Inge Marie Svane
Poster
2015 ASCO Annual Meeting
A multi-center phase II study of high dose IL-2 (HD IL-2) sequenced with vemurafenib in patients with BRAF-V600E mutation positive advanced melanoma.
First Author: Joseph Clark